Patents by Inventor Richard G. Wyatt

Richard G. Wyatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine against rotavirus diseases
    Patent number: 4751080
    Abstract: The present invention discloses a vaccine for the prevention of rotavirus caused diseases in humans. The vaccine is prepared from attenuated, immunogenic rhesus rotavirus which has been characterized to be antigenically similar, if not identical, to human rotavirus serotype 3.
    Type: Grant
    Filed: July 31, 1987
    Date of Patent: June 14, 1988
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Richard G. Wyatt, Albert Z. Kapikian, Robert M. Chanock, Karen Midthun, Jorge Flores, Yasutaka Hoshino
  • Vaccine against rotavirus diseases
    Patent number: 4704275
    Abstract: The present invention discloses a vaccine for the prevention of rotavirus caused diseases in humans. The vaccine is prepared from attenuated, immunogenic rhesus rotavirus which has been characterized to be antigenically similar, if not identical, to human rotavirus serotype 3.
    Type: Grant
    Filed: August 26, 1985
    Date of Patent: November 3, 1987
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Richard G. Wyatt, Albert Z. Kapikian, Robert M. Chanock, Karen Midthun, Jorge Flores, Yasutaka Hoshino
  • Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
    Patent number: 4571385
    Abstract: This invention relates to processes which are used to produce, isolate, and characterize human rotavirus/animal rotavirus reassortants and to produce live attenuated vaccines and vaccine precursors. In the present strategy there is involved the new use of either (1) high titer hyperimmune antisera or (2) monoclonal antisera to select reassortants with the desired human phenotype. A point of novelty is the finding that antiserum or monoclonal antisera alone, so long as it possesses high titer neutralizing activity against only the 34-38Kd glycoprotein or of the animal parent, is sufficient to use for selection of reassortant rotaviruses with human phenotype. Also, the novel products are live attenuated vaccine precursors and vaccines.
    Type: Grant
    Filed: June 27, 1983
    Date of Patent: February 18, 1986
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Harry B. Greenberg, Richard G. Wyatt, Albert Z. Kapikian, Anthony R. Kalica, Karen Midthun, Robert M. Chanock
  • Cultivatable human rotavirus type 2
    Patent number: 4341870
    Abstract: This invention relates to a precursor or intermediate for a rotavirus vaccine to protect infants and young children against diarrhea caused by rotavirus. The invention is the efficient propagation of a strain of human rotavirus type 2 prepared by a method of cultivation by multiple passages in vivo in gnotobiotic piglets and by multiple passages in vitro subsequently in AGMK (African green monkey kidney) cell cultures. Additionally, rotavirus is treated with a biologically active amount of trypsin prior to growth in AGMK cells, and the inoculated cell cultures are centrifuged at a low centrifugal force before incubation.
    Type: Grant
    Filed: November 19, 1980
    Date of Patent: July 27, 1982
    Assignee: The United States of America as represented by the Secretary of the Department of Health & Human Services
    Inventors: Richard G. Wyatt, Walter D. James, Edward H. Bohl, Kenneth W. Theil, Linda J. Saif, Anthony R. Kalica, Harry B. Greenberg, Albert Z. Kapikian, Robert M. Chanock